Fox Run Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

Fox Run Management’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-4,499	Closed	-$348K	–	1255
2026 Q1	$348K	Buy	+4,499	New	+$438K	0.06%	586
2025 Q4	–	Sell	-2,517	Closed	-$254K	–	1215
2025 Q3	$254K	Buy	+2,517	New	+$234K	0.04%	738
2025 Q2	–	Sell	-19,172	Closed	-$1.02M	–	1180
2025 Q1	$1.02M	Buy	+19,172	New	+$1.06M	0.16%	202
2023 Q4	–	Sell	-17,186	Closed	-$394K	–	983
2023 Q3	$394K	Buy	+17,186	New	+$385K	0.12%	348
2023 Q2	–	Sell	-37,950	Closed	-$677K	–	927
2023 Q1	$677K	Buy	+37,950	New	+$953K	0.22%	146

Other funds holding RYTM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fox Run Management's RYTM Position: Q2 2026 in Review

Fox Run Management sold out of Rhythm Pharmaceuticals (RYTM) in Q2 2026, closing a stake of 4,499 shares — an estimated $348K sold.

Fox Run Management first reported a position in RYTM in Q1 2023 and held it in 5 quarters. The position peaked at $1.02M in Q1 2025. 304 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

Fox Run Management reported no remaining Rhythm Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Fox Run Management sold 4,499 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $348K.
Fox Run Management first reported a position in Rhythm Pharmaceuticals in Q1 2023 and held it in 5 quarters.
Fox Run Management's Rhythm Pharmaceuticals position peaked at $1.02M in Q1 2025.
304 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Fox Run Management's 13F filing for Q2 2026, filed 4 Aug 2026.